Belinostat Suppresses Bladder Cancer Growth
Author Information
Author(s): Michael T Buckley, Joanne Yoon, Herman Yee, Luis Chiriboga, Leonard Liebes, Gulshan Ara, Xiaozhong Qian, Dean F Bajorin, Tung-Tien Sun, Xue-Ru Wu, Iman Osman
Primary Institution: New York University School of Medicine
Hypothesis
Does belinostat effectively inhibit bladder cancer cell growth in vitro and in vivo?
Conclusion
Belinostat inhibits bladder cancer and supports its clinical evaluation for treating superficial bladder cancer.
Supporting Evidence
- Belinostat caused a significant dose-dependent growth inhibition in all tested bladder cancer cell lines.
- The 5637 cell line was the most sensitive to belinostat treatment.
- Belinostat-treated mice showed less bladder weight and no hematuria compared to control mice.
- IHC analysis indicated increased expression of p21WAF1 in belinostat-treated mice.
Takeaway
Belinostat is a medicine that helps stop bladder cancer from growing in mice and might help people with bladder cancer too.
Methodology
The study assessed the effects of belinostat on bladder cancer cell lines and a transgenic mouse model, measuring growth inhibition and cell cycle distribution.
Limitations
The study primarily used a transgenic mouse model, which may not fully replicate human bladder cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website